Incretină (Romanian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Incretină" in Romanian language version.

refsWebsite

Global rank Romanian rank

6doi.org

2^nd place

3^rd place

6nih.gov

4^th place

4fda.gov

447^th place

173^rd place

3medscape.com

719^th place

901^st place

1worldcat.org

5^th place

11^th place

1diabet-si-nutritie.ro

low place

diabet-si-nutritie.ro

„Incretine”, Diabet, Nutriție și Boli Metabolice, 25 decembrie 2017, accesat în 22 decembrie 2020

doi.org

Drucker DJ, Nauck MA (noiembrie 2006). „The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes”. Lancet. 368 (9548): 1696–705. doi:10.1016/S0140-6736(06)69705-5. PMID 17098089.
Amori RE, Lau J, Pittas AG (iulie 2007). „Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis”. JAMA. 298 (2): 194–206. doi:10.1001/jama.298.2.194. PMID 17622601.
Ali ES, Hua J, Wilson CH, Tallis GA, Zhou FH, Rychkov GY, Barritt GJ (2016). „The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca2+ signalling in steatotic hepatocytes”. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1863 (9): 2135–46. doi:10.1016/j.bbamcr.2016.05.006 . PMID 27178543.
McIntosh, C; Demuth, H; Pospisilik, J; Pederson, R (2005). „Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?”. Regulatory Peptides. 128 (2): 159–65. doi:10.1016/j.regpep.2004.06.001. PMID 15780435.
Behme, Margaret T; Dupré, John; McDonald, Thomas J (2003). „Glucagon-like peptide 1 improved glycemic control in type 1 diabetes”. BMC Endocrine Disorders. 3 (1): 3. doi:10.1186/1472-6823-3-3. PMC 154101 . PMID 12697069.
Dupre, J.; Behme, M. T.; Hramiak, I. M.; McFarlane, P.; Williamson, M. P.; Zabel, P.; McDonald, T. J. (1995). „Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM”. Diabetes. 44 (6): 626–30. doi:10.2337/diabetes.44.6.626. PMID 7789625.

fda.gov

„FDA Approves New Treatment for Type 2 Diabetes”.
„FDA approves Adlyxin to treat type 2 diabetes”. 10 septembrie 2019.
„FDA Approves Weekly Injectable Diabetes Drug: Dulaglutide”.
„FDA approves new treatment for Type 2 diabetes”. Fda.gov. 2 mai 2011. Accesat în 15 aprilie 2013.

medscape.com

Baggio LL (2008). „Glucagon-like Peptide-1 Analogs Other Than Exenatide”. Medscape Diabetes & Endocrinology.
„FDA Approves Weekly Injectable Diabetes Drug: Albiglutide”.
Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes. 2013

nih.gov

ncbi.nlm.nih.gov

Drucker DJ, Nauck MA (noiembrie 2006). „The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes”. Lancet. 368 (9548): 1696–705. doi:10.1016/S0140-6736(06)69705-5. PMID 17098089.
Amori RE, Lau J, Pittas AG (iulie 2007). „Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis”. JAMA. 298 (2): 194–206. doi:10.1001/jama.298.2.194. PMID 17622601.
Ali ES, Hua J, Wilson CH, Tallis GA, Zhou FH, Rychkov GY, Barritt GJ (2016). „The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca2+ signalling in steatotic hepatocytes”. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1863 (9): 2135–46. doi:10.1016/j.bbamcr.2016.05.006 . PMID 27178543.
McIntosh, C; Demuth, H; Pospisilik, J; Pederson, R (2005). „Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?”. Regulatory Peptides. 128 (2): 159–65. doi:10.1016/j.regpep.2004.06.001. PMID 15780435.
Behme, Margaret T; Dupré, John; McDonald, Thomas J (2003). „Glucagon-like peptide 1 improved glycemic control in type 1 diabetes”. BMC Endocrine Disorders. 3 (1): 3. doi:10.1186/1472-6823-3-3. PMC 154101 . PMID 12697069.
Dupre, J.; Behme, M. T.; Hramiak, I. M.; McFarlane, P.; Williamson, M. P.; Zabel, P.; McDonald, T. J. (1995). „Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM”. Diabetes. 44 (6): 626–30. doi:10.2337/diabetes.44.6.626. PMID 7789625.

worldcat.org

Rang HP, Ritter JM, Flower R, Henderson G (2016). Rang and Dale's Pharmacology (ed. 8th). United Kingdom: Elsevier Churchill Livingstone. p. 385. ISBN 9780702053627. OCLC 903083639.